Graves‘病患者血清可溶性Fas检测及其临床意义

目的 探讨可溶性Ｆａｓ（ｓＦａｓ）在Ｇｒａｖｅｓ’病（ＧＤ）发病过程中的作用。方法 应用夹心酶联免疫吸附法（ＥＬＩＳＡ），测定了６８例ＧＤ患者和２０例健康对照者ｓＦａｓ含量。结果 ①ＧＤ患者术治疗组和缓解组血清ｓＦａｓ同于健康对照组；②ＧＤ患者未治疗组和缓解组ｓＦａｓ。ＴＲＡｂ乘积高于健康对照组；③血清ｓＦａｓ与ＴＲＡｂ呈正相关关系，与游离Ｔ３、游离Ｔ４和促甲状腺素（ＴＳＨ）无相关关系。结论 ｓＦａｓ参与了ＧＤ发病与转归的病理生理过程，可以作为ＧＤ病情监测的重要指标。

Measurement of serum soluble Fas in patients with Graves

Objective To investigate the concentration of soluble sFas（sFas）in Graves’disease（GD） and its clinical significance.Methods Serum levels of sFas in 68 cases of GD patients and 20 cases of healthy subjects were measured with a sandwiched ELISA method.Results ①Serum sFas levels of GD untreated group and remission group were much higher than those of healthy controls（2.08±0.82， 1.11±0.31 vs 0.70±0.5 0 ng／mL，P＜0.001）；② Multiplier of sFas.TRAb in GD untreated group and remission group were much higher than those of healthy controls（80.01±57.62， 3.34±1.69 vs 0.81±0.80，P＜0.001）；③The concentration of serum sFas was significantly correlated with anti-thyrotropin（TSH） receptor antibody titers（r＝0.309，P＜0.05），but not with other clinical parameters（free triiodothyronine，free thyroxine and TSH）（r＝0.041—0.146，P＞0.05）.Conclusion Serum sFas may play a pivotal role in the pathogenesis of GD.